1152 related articles for article (PubMed ID: 9140726)
1. Reactivity to tyrosinase: expression in cancer (melanoma) and autoimmunity (vitiligo).
Merimsky O; Shoenfeld Y; Baharav E; Zigelman R; Fishman P
Hum Antibodies Hybridomas; 1996; 7(4):151-6. PubMed ID: 9140726
[TBL] [Abstract][Full Text] [Related]
2. Autoantibodies to tyrosinase: the bridge between melanoma and vitiligo.
Fishman P; Merimski O; Baharav E; Shoenfeld Y
Cancer; 1997 Apr; 79(8):1461-4. PubMed ID: 9118024
[TBL] [Abstract][Full Text] [Related]
3. Harnessing autoimmunity (vitiligo) to treat melanoma: a myth or reality?
Ram M; Shoenfeld Y
Ann N Y Acad Sci; 2007 Sep; 1110():410-25. PubMed ID: 17911456
[TBL] [Abstract][Full Text] [Related]
4. Melanoma-associated hypopigmentation: where are the antibodies?
Merimsky O; Shoenfeld Y; Baharav E; Altomonte M; Chaitchik S; Maio M; Ferrone S; Fishman P
Am J Clin Oncol; 1996 Dec; 19(6):613-8. PubMed ID: 8931683
[TBL] [Abstract][Full Text] [Related]
5. The clinical significance of antityrosinase antibodies in melanoma and related hypopigmentary lesions.
Merimsky O; Shoenfeld Y; Fishman P
Clin Rev Allergy Immunol; 1998; 16(3):227-36. PubMed ID: 9773250
[TBL] [Abstract][Full Text] [Related]
6. Definition of anti-tyrosinase MAb T311 linear determinant by proteome-based similarity analysis.
Willers J; Lucchese A; Mittelman A; Dummer R; Kanduc D
Exp Dermatol; 2005 Jul; 14(7):543-50. PubMed ID: 15946243
[TBL] [Abstract][Full Text] [Related]
7. Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells.
Cui J; Bystryn JC
Arch Dermatol; 1995 Mar; 131(3):314-8. PubMed ID: 7887661
[TBL] [Abstract][Full Text] [Related]
8. Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo.
Uchi H; Stan R; Turk MJ; Engelhorn ME; Rizzuto GA; Goldberg SM; Wolchok JD; Houghton AN
Adv Immunol; 2006; 90():215-41. PubMed ID: 16730265
[TBL] [Abstract][Full Text] [Related]
9. Autoimmune vitiligo: detection of antibodies to melanin-producing cells.
Hertz KC; Gazze LA; Kirkpatrick CH; Katz SI
N Engl J Med; 1977 Sep; 297(12):634-7. PubMed ID: 331108
[TBL] [Abstract][Full Text] [Related]
10. Tyrosinase as an autoantigen in patients with vitiligo.
Baharav E; Merimski O; Shoenfeld Y; Zigelman R; Gilbrud B; Yecheskel G; Youinou P; Fishman P
Clin Exp Immunol; 1996 Jul; 105(1):84-8. PubMed ID: 8697641
[TBL] [Abstract][Full Text] [Related]
11. Autoimmunity as an aetiological factor in vitiligo.
Rezaei N; Gavalas NG; Weetman AP; Kemp EH
J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):865-76. PubMed ID: 17658994
[TBL] [Abstract][Full Text] [Related]
12. Tumor antigens isolated from a patient with vitiligo and T-cell-infiltrated melanoma.
Kiniwa Y; Fujita T; Akada M; Ito K; Shofuda T; Suzuki Y; Yamamoto A; Saida T; Kawakami Y
Cancer Res; 2001 Nov; 61(21):7900-7. PubMed ID: 11691810
[TBL] [Abstract][Full Text] [Related]
13. The role of tyrosinase in autoimmune vitiligo.
Song YH; Connor E; Li Y; Zorovich B; Balducci P; Maclaren N
Lancet; 1994 Oct; 344(8929):1049-52. PubMed ID: 7934446
[TBL] [Abstract][Full Text] [Related]
14. [Humoral and cellular autoimmunity in genuine vitiligo studied by means of an antigen produced from melanoma cells].
Höfs T
Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(2):244-50. PubMed ID: 6179826
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of experimental autoimmune vitiligo by oral administration of mushroom tyrosinase.
Zehtab T; Yazdanparast R; Rafieii S
Cytobios; 2001; 105(408):27-34. PubMed ID: 11368265
[TBL] [Abstract][Full Text] [Related]
16. Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo.
Dorđić M; Matić IZ; Filipović-Lješković I; Džodić R; Sašić M; Erić-Nikolić A; Vuletić A; Kolundžija B; Damjanović A; Grozdanić N; Nikolić S; Pralica J; Dobrosavljević D; Rašković S; Andrejević S; Juranić Z
BMC Complement Altern Med; 2012 Jul; 12():109. PubMed ID: 22834951
[TBL] [Abstract][Full Text] [Related]
17. Anti-tyrosinase antibodies in malignant melanoma.
Merimsky O; Baharav E; Shoenfeld Y; Chaitchik S; Tsigelman R; Cohen-Aloro D; Fishman P
Cancer Immunol Immunother; 1996 Jun; 42(5):297-302. PubMed ID: 8706052
[TBL] [Abstract][Full Text] [Related]
18. Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy.
Okamoto T; Irie RF; Fujii S; Huang SK; Nizze AJ; Morton DL; Hoon DS
J Invest Dermatol; 1998 Dec; 111(6):1034-9. PubMed ID: 9856813
[TBL] [Abstract][Full Text] [Related]
19. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.
Rosenberg SA; White DE
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):81-4. PubMed ID: 8859727
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibodies produced against murine tyrosinase identify pigmented human melanocytes.
Tomita Y; Hearing VJ
Diagn Immunol; 1986; 4(3):149-54. PubMed ID: 3089671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
